2. Signaling Pathways
  3. GPCR/G Protein
    MAPK/ERK Pathway
  4. Ras

Ras

Ras

Related Products

PDF 2.6 MB

Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.

Ras Isoform Specific Products:

Ras Isoform Comparison
Cat. No. Product Name Effect Purity Chemical Structure
  • HY-152248
    ARS-2102
    		Inhibitor
    ARS-2102 is a potent covalent KRAS G12C inhibitor for use in cancer research.
    ARS-2102
  • HY-161635
    SOS1 Ligand intermediate-4
    		Inhibitor
    SOS1 Ligand intermediate-4 is a ligand of SOS1, used for the synthesis of PROTAC SOS1 degrader (HY-161634).
    SOS1 Ligand intermediate-4
  • HY-124126
    NSC 1008
    		Inhibitor
    NSC 1008 is a selective Ras converting enzyme 1 (Rce1) inhibitor that reduces Rce1 in vitro activity with a human IC50 of 8.9 μM. NSC 1008 demonstrates selectivity for Rce1 by not inhibiting human Ste24 or huamn FTase. NSC 1008 exhibits low cell toxicity, and induces mislocalization of EGFP-Ras from the plasma membrane in cancer cells. NSC 1008 can be used for the research of cancer.
    NSC 1008
  • HY-122152
    Spiclomazine hydrochloride
    		Inhibitor
    Spiclomazine hydrochloride (APY-606) is an antipsychotic and antitumor agent. Spiclomazine hydrochloride inhibits KRas. Spiclomazine hydrochloride induces cancer cell apoptosis.
    Spiclomazine hydrochloride
  • HY-178875
    Nrf2 activator-22
    Nrf2 activator-22, a Nrf2 activator, is a PROTAC target protein ligand. Nrf2 activator-22 can be used for synthesis PROTAC K-Ras Degrader-7 (HY-178873).
    Nrf2 activator-22
  • HY-124755
    RAS activator compound 1
    		Activator 98.90%
    RAS activator compound 1 (Compound 7c) is a RAS activator targeting the guanine nucleotide exchange factor (GEF) son of sevenless homologue 1 (SOS1). RAS activator compound 1 can activate the nucleotide exchange process and increase levels of active RAS-GTP in HeLa cells. RAS activator compound 1 can be used for research of RAS-driven tumor.
    RAS activator compound 1
  • HY-153880
    KRAS degrader-1
    		Degrader
    KRAS degrader-1 is a potent KRAS degrader. KRAS degrader-1 targets specific proteins for degradation via the autophagy-lysosomal degradation pathway. KRAS degrader-1 is suitable for use in cancer research. (Blue: KRAS G12C-IN-72 (HY-128414); Black: Linker (HY-175587); Pink: 5-Iodoindolin-2-one (HY-76986); Blue + Black: KRAS ligand-Linker Conjugate 7 (HY-175586)).
    KRAS degrader-1
  • HY-151999
    KRAS G12C inhibitor 65
    		Inhibitor
    KRAS G12C inhibitor 65 is a potent and covalent KRASG12C inhibitor that traps KRASG12C in the GDP-bound state. KRASG12C IN-1 exhibits potent antitumor activity against KRAS-mutant non-small cell lung cancer.
    KRAS G12C inhibitor 65
  • HY-143592
    KRAS G12C inhibitor 39
    		Inhibitor
    KRAS G12C inhibitor 39 is a potent inhibitor of KRAS G12C. KRas is a highly attractable target of the pharmaceutical industry for cancer research. KRAS G12C inhibitor 39 has the potential for the research of KRAS G12C-mediated cancer (extracted from patent WO2019099524A1, compound 494).
    KRAS G12C inhibitor 39
  • HY-173632A
    AMG410 diTFA
    		Inhibitor
    AMG410 diTFA is a non-covalent and selective pan-KRAS inhibitor with IC50 values of 1-4 nM for KRAS G12D, KRAS G12V, and KRAS G13D. AMG410 diTFA shows greater than 100-fold selectivity against both HRAS and NRAS. AMG410 diTFA is a dual GTP(on)- and GDP(off)-state inhibitor (Kd(GDP-state) of 1 nM; Kd(GTP-state) of 22 nM). AMG410 diTFA blocks KRAS signaling in a cycling state-independent manner and also blocks proliferation in wildtype KRAS-amplified tumor cells. AMG410 diTFA can be used for the study of colorectal, pancreatic, and lung cancers.
    AMG410 diTFA
  • HY-145046
    SOS1-IN-3
    		Inhibitor
    SOS1-IN-3 is a potent SOS1 (son of sevenless homolog 1) inhibitor with an IC50 of 5 nM. SOS1-IN-3 has anticancer effects (WO2019122129A1; compound I-1).
    SOS1-IN-3
  • HY-146537
    KRAS G12C inhibitor 47
    		Inhibitor
    KRAS G12C inhibitor 47 (compound 8-1-1) is a potent KRAS G12C inhibitor with an IC50 of 0.172 µM. KRAS G12C inhibitor 47 shows p-ERK inhibition activities with IC50s of 0.046, 69.8 µM in MIA PaCA-2, A549 cells, respectively. KRAS G12C inhibitor 47 has the potential for the research of pancreatic, colorectal, and lung cancers.
    KRAS G12C inhibitor 47
  • HY-156671B
    RMC-4998 TFA
    		Inhibitor 99.02%
    RMC-4998 TFA is an orally active inhibitor targeting the active or GTP-bound state of the KRASG12C mutant. RMC-4998 TFA can form a ternary complex with intracellular CYPA and the activated KRASG12C mutant, with an IC50 value of 28 nM. RMC-4998 TFA can inhibit ERK signaling in KRASG12C mutant cancer cells and induce apoptosis. RMC-4998 TFA can be used for for non-small cell lung cancer (NSCLC) research.
    RMC-4998 TFA
  • HY-158701
    KRAS G12D inhibitor 23
    		Inhibitor
    KRAS G12D inhibitor 23 (compound 46-3) is a potent inhibitor of KRAS G12D, with the IC50 of 0.007 μM. KRAS G12D inhibitor 23 plays an important role in cancer research.
    KRAS G12D inhibitor 23
  • HY-168577
    KRAS G12D inhibitor 25
    		Inhibitor
    KRAS G12D inhibitor 25 (Compound 148) is an inhibitor for KRAS G12C and HSP90α with IC50 of < 0.1 μM and 0.1-1 μM, respectively. KRAS G12D inhibitor 25 inhibits the proliferation of MIA PaCa-2 and NCI-H358 with EC50 of < 0.1 μM and 0.1-1 μM, respectively. KRAS G12D inhibitor 25 degrades ERBB2 with a DC50 of 0.1-1 μM.
    KRAS G12D inhibitor 25
  • HY-146545
    KRAS inhibitor-15
    		Inhibitor
    KRAS inhibitor-15 (compound 3-19) is a potent KRAS G12C inhibitor with an IC50 of 0.954 µM. KRAS inhibitor-15 shows p-ERK inhibition activities with IC50s of 2.03, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-15 has the potential for the research of pancreatic, colorectal, and lung cancers.
    KRAS inhibitor-15
  • HY-179318
    KRAS G12D-IN-32
    		Inhibitor
    KRAS G12D-IN-32 (Page 158) is a KRAS G12D inhibitor. KRAS G12D-IN-32 can be used to study adenocarcinoma, colorectal cancer, and non-small cell lung cancer.
    KRAS G12D-IN-32
  • HY-P990146
    Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238)
    		Inhibitor
    Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) is an anti-mouse/rat/human v-H-Ras IgG2a monoclonal antibody. Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) can be used as a control antibody. Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238) is often used for immunofluorescence and immunoprecipitation.
    Anti-Mouse/Rat/Human v-H-Ras Antibody (Y13-238)
  • HY-116312
    8-pCPT-2′-O-Me-cAMP
    		Activator
    8-pCPT-2′-O-Me-cAMP (8-CPT-2'-O-Me-cAMP), an analog of cAMP, is an activator of exchange proteins activated by cAMP (Epac). 8-pCPT-2′-O-Me-cAMP activates Epac1 (EC50 = 2.2 μM), but not PKA (EC50 >10 μM). 8-pCPT-2′-O-Me-cAMP stimulates Epac-mediated Ca2+ release in pancreatic β-cells in vitro. 8-pCPT-2′-O-Me-cAMP is a Rap1 activator. 8-pCPT-2′-O-Me-cAMP enhances the retinal pigment epithelium barrier against the pathological choroidal endothelial cell invasion that occurs in macular degeneration.
    8-pCPT-2′-O-Me-cAMP
  • HY-179536
    KRAS-IN-49
    		Inhibitor
    KRAS-IN-49 (compound 7b) is a selective and covalent KRAS G13C inhibitor. KRAS-IN-49 covalently binds to Cys13 of KRAS G13C. KRAS-IN-49 can be used for non-small cell lung cancer (NSCLC) research.
    KRAS-IN-49
Cat. No. Product Name / Synonyms Application Reactivity
Ras Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.